The first FDA/KFDA/CE-certified dermal solution combining 170mg PDLLA with 30mg non-crosslinked HA. Clinically proven to stimulate Type I/III collagen production (82% improvement over 24 months) while delivering immediate volumizing effects through hygroscopic hydration. Validated in 3 clinical trials with 92% patient satisfaction.

*Prescription medical device. Results may vary (15-30% differential across skin types). Contraindicated in patients with active infections or hypersensitivity to polylactic acid. Administer only by licensed practitioners with dermal injection certification.